In contrast, subtypes 1 and 2 are related to immune-related processes and TP53 mutations, suggesting late-stage cancer; subtype 3 showed enrichment in cell cycle dysregulation, and subtype 4 had an extracellular matrix organization signature [96]. Here, TP53 is linked to cancer.